Oligonucleotide News and Research

RSS

Research shows how remdesivir inhibits SARS-CoV-2 replication

In a recent bioRxiv preprint, a research team from Germany, Goran Kokic et al. study the molecular mechanism of remdesivir-induced stalling of RdRp - using synthetic RNA chemistry, biochemistry, and cryo-electron microscopy.

2 Nov 2020

Research projects receive BTCA grants to develop novel drugs for various diseases

Five research projects with exceptional promise to deliver new life-changing and health-altering therapies have received the inaugural Blavatnik Therapeutics Challenge Awards (BTCA) at Harvard Medical School.

30 Oct 2020

Researchers develop new strategy to improve siRNA stability

RNA interference is a gene regulatory mechanism in which the expression of specific genes is downregulated by endogenous microRNAs or by small interfering RNAs (siRNAs).

16 Oct 2020

Challenges in High Complexity Flow Cytometry

In this interview, Dra. Mª José Marco from the Department of Hematology at Hopsital Dr. Peset talks to News-Medical Life Sciences about high complexity flow cytometry and the challenges they often face.

From Beckman Coulter Life Sciences - Flow Cytometry 24 Sep 2020

Inhibition of SARS-CoV-2 with antisense oligonucleotides

A part of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral RNA is highly conserved. Researchers have used this as a target for designing antisense oligonucleotide gapmers to cleave the RNA and disrupt virus replication. Their research is published as a preprint on the online server bioRxiv in September 2020.

22 Sep 2020

Investigational drug may reduce protein buildup and neurological decline linked to ALS, FTD

An investigational drug that targets an instigator of the TDP-43 protein, a well-known hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), may reduce the protein's buildup and neurological decline associated with these disorders, suggests a pre-clinical study from researchers at Penn Medicine and Mayo Clinic.

8 Sep 2020

Serum protein shows therapeutic value against severe COVID-19-like features in mouse model

A new study published on the preprint server bioRxiv* in August 2020 reports the disease-mitigating effects of a serum protein called serum amyloid P (SAP) in mice exposed to a peptide that mimics the clinical signs of severe COVID-19 in humans.

30 Aug 2020

Researchers develop vaccine for human herpesvirus 6B

A research group led by Professor MORI Yasuko (of the Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine) has revealed that the HHV-6B glycoprotein complex gH/gL/gQ1/gQ2 is an effective vaccine candidate for human herpesvirus 6B (HHV-6B).

20 Aug 2020

FDA approves new treatment option for patients with rare Duchenne muscular dystrophy mutation

Today, the U.S. Food and Drug Administration granted accelerated approval to Viltepso (viltolarsen) injection for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.

12 Aug 2020

Study: Anti-microRNA drug significantly reduces miR-92a levels in human peripheral blood

A single intravenous dose of MRG-110, an anti-microRNA drug, significantly reduced miR-92a levels in the blood of healthy humans.

12 Aug 2020

Picomolar inhibitors to SARS-CoV-2 proteins

Now, a new study published on the preprint server bioRxiv in August 2020 reports the development of mini-inhibitors based on computational design, that are suitable for such topical use.

4 Aug 2020

Researchers develop new therapeutic approach to treat CLN3 Batten disease

Researchers led by a team at Rosalind Franklin University of Medicine and Science have devised a new therapeutic approach to treating a rare but deadly neurodegenerative genetic disease in children.

31 Jul 2020

Neurotransmitter-derived lipidoids help carry drugs across the blood-brain barrier in mice

Biomedical engineers at the Tufts University School of Engineering have developed tiny lipid-based nanoparticles that incorporate neurotranmitters to help carry drugs, large molecules, and even gene editing proteins across the blood-brain barrier and into the brain in mice.

24 Jul 2020

Study: L-Grb2 has therapeutic efficacy in preclinical models of ovarian and uterine cancer

The cover for issue 29 of Oncotarget features, "In vivo effects of treatment with L-Grb2 in combination with anti-angiogenic therapy in an ovarian tumor model," by Lara, et al. which reported that adaptor proteins such as growth factor receptor-bound protein-2 play important roles in cancer cell signaling.

23 Jul 2020

Experimental drug for rare ALS shows promise in early clinical trial

An experimental drug for a rare, inherited form of amyotrophic lateral sclerosis (ALS) has shown promise in a phase 1/phase 2 clinical trial conducted at Washington University School of Medicine in St. Louis, Massachusetts General Hospital in Boston and other sites around the world and sponsored by the pharmaceutical company Biogen Inc.

8 Jul 2020

Developing Vaccines and Therapeutics by Exploiting Structure in Spherical Nucleic Acids

An interview discussing the use of spherical nucleic acids (SNAs) and what they show about the importance of structure in pharmaceutical development.

From Pittcon 2 Jul 2020

Structure of the full SARS-CoV-2 RNA genome in infected cells

The current COVID-19 pandemic caused by a single-stranded RNA virus, thought to have jumped across species barriers to infect humans, has spread rapidly across the globe infecting over 10 million individuals. The virus, now known as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is the causative agent of COVID-19 disease. COVID-19 disease is a respiratory illness where symptoms can range from very mild to severe and include fever, coughing, a sore throat, and shortness of breath.

2 Jul 2020

Researchers develop a potential treatment approach for Pelizaeus-Merzbacher disease

A team led by Case Western Reserve University medical researchers has developed a potential treatment method for Pelizaeus-Merzbacher disease (PMD), a fatal neurological disorder that produces severe movement, motor and cognitive dysfunction in children.

1 Jul 2020

Researchers develop potential new therapy for common form of muscular dystrophy

Researchers have designed a potential new treatment for one of the most common forms of muscular dystrophy, according to a new study published today in the Proceedings of the National Academy of Sciences.

29 Jun 2020

Parkinson's disease breakthrough seen in mouse model

Researchers from the University of California San Diego School of Medicine have found a way to create new neurons in a mouse model of Parkinson's disease. The severely debilitating and progressive neurodegenerative disease, as of now, has no cure, and this breakthrough could help hundreds of thousands of patients with the condition feel experts.

25 Jun 2020